Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Solid Tumours × Cytochrome P-450 CYP2C19 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumours 1

Interventions

AZD 6244 5 GSK 1363089 3 pazopanib 1 ispinesib 1 Topotecan 1 SLC-0111 1 Rifampin 1 Omeprazole 1 Moxifloxacin 1 Midazolam 1 Itraconazole 1 Granisetron 1 Fluconazole 1 Famotidine 1 Cytochrome P-450 CYP3A 1 Cytochrome P-450 CYP2C19 1 Cytochrome P-450 CYP1A2 1 Carboplatin 1 Carbon-14 1 Caffeine 1 BGC945 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03333824 2019-03-25

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed

Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon ⚡